Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

PROF earnings analysis

Filed May 7, 2026 · Our reading of the company's report

The latest report

Profound Medical reported Q1 2026 revenue of $5.3 million, a 104% increase from $2.6 million in Q1 2025, marking significant growth as net loss improved to $7.0 million from $10.7 million year-over-year. The company…

Read full summary

Profound Medical reported Q1 2026 revenue of $5.3 million, a 104% increase from $2.6 million in Q1 2025, marking significant growth as net loss improved to $7.0 million from $10.7 million year-over-year. The company achieved a gross margin of 72%, reflecting a slight increase from prior periods, with decreased operating expenses contributing to the narrower loss.

Read the original on SEC.gov

Reported figures

Earnings per share
$0.19
Gross margin
72%
Segment
TULSA-PRO
Segment
Sonalleve

What stood out

  • Revenue Up 104% Year-Over-Year

    Revenue grew to $5.3 million from $2.6 million in Q1 2025.

  • Narrowed Net Loss

    Net loss improved to $7.0 million from $10.7 million in the prior year.

  • Operating Expenses Reduced

    Total operating expenses decreased by 9% to $11.9 million from $13.0 million in Q1 2025.

  • High Gross Margin Maintained

    Gross margin remains strong at 72%, slightly up from 71% in the previous year.

  • Increased Product Adoption

    Capital equipment sales significantly contributed to revenue growth.

  • Decreased SG&A Expenses

    SG&A expenses dropped by 20% to $6.6 million from $8.2 million.

What to watch

  • High Operating Expenses Persist

    Operating expenses remain high at $11.9 million despite reductions.

  • Clinical Trials Dependency

    The company's growth is closely tied to the success of ongoing clinical trials.

  • Market Acceptance Risks

    Continued revenue growth depends on broader market acceptance of TULSA-PRO and Sonalleve.

Management's outlook

Management anticipates full-year 2026 revenue of approximately $25 million, marking a targeted 56% growth from the previous year.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.